,NR 565 Final Exam | Adv Pharmacology Fundamentals
(2026) Actual Q&A PDF | Chamberlain
1. A patient asks how an oral medication produces its effects. The nurse practitioner
explains that the process of drug absorption, distribution, metabolism, and excretion is
known as:
A) Pharmacodynamics
B) Pharmacotherapeutics
C) Pharmacokinetics
D) Pharmacogenomics
Correct Answer: Pharmacokinetics
Rationale: Pharmacokinetics is the study of drug movement throughout the body,
including absorption, distribution, metabolism, and excretion (ADME).
Pharmacodynamics describes what the drug does to the body, pharmacotherapeutics is
the clinical use of drugs, and pharmacogenomics studies genetic influences on drug
response.
2. A drug that binds to a receptor and produces a response less than that of a full
agonist, even at maximal concentrations, is known as a:
A) Partial agonist
B) Inverse agonist
C) Competitive antagonist
,D) Non-competitive antagonist
Correct Answer: Partial agonist
Rationale: A partial agonist has lower efficacy than a full agonist and cannot produce
a maximal response even when all receptors are occupied. An inverse agonist reduces
baseline activity, while competitive and non-competitive antagonists block agonist
effects without producing a response.
3. Which pharmacokinetic parameter is defined as the proportion of an administered
drug that reaches systemic circulation in an unchanged form?
A) Bioavailability
B) Therapeutic index
C) Half-life
D) Clearance
Correct Answer: Bioavailability
Rationale: Bioavailability (F) measures the fraction of an administered dose that enters
systemic circulation unchanged. The therapeutic index is a safety ratio, half-life is the
time for drug concentration to decrease by 50%, and clearance is the volume of blood
cleared of drug per unit time.
4. A patient with cirrhosis is prescribed a medication that undergoes extensive first-pass
hepatic metabolism. The nurse practitioner anticipates which change in bioavailability?
, A) Decreased bioavailability due to impaired absorption
B) Increased bioavailability due to reduced first-pass metabolism
C) Unchanged bioavailability because first-pass metabolism occurs in the intestines
D) Variable bioavailability depending on renal function
Correct Answer: Increased bioavailability due to reduced first-pass metabolism
Rationale: Cirrhosis reduces hepatic function, decreasing first-pass metabolism and
increasing the fraction of drug reaching systemic circulation. This can lead to higher
drug levels and increased risk of toxicity, often requiring dose reduction.
5. A medication with a narrow therapeutic index requires which monitoring approach?
A) Less frequent monitoring due to a wide safety margin
B) Close monitoring of serum drug levels
C) No special precautions
D) Higher doses to ensure efficacy
Correct Answer: Close monitoring of serum drug levels
Rationale: Drugs with a narrow therapeutic index have a small margin between
therapeutic and toxic doses, making serum level monitoring essential. Examples include
digoxin, lithium, warfarin, and phenytoin. Monitoring ensures levels remain within the
therapeutic range.
(2026) Actual Q&A PDF | Chamberlain
1. A patient asks how an oral medication produces its effects. The nurse practitioner
explains that the process of drug absorption, distribution, metabolism, and excretion is
known as:
A) Pharmacodynamics
B) Pharmacotherapeutics
C) Pharmacokinetics
D) Pharmacogenomics
Correct Answer: Pharmacokinetics
Rationale: Pharmacokinetics is the study of drug movement throughout the body,
including absorption, distribution, metabolism, and excretion (ADME).
Pharmacodynamics describes what the drug does to the body, pharmacotherapeutics is
the clinical use of drugs, and pharmacogenomics studies genetic influences on drug
response.
2. A drug that binds to a receptor and produces a response less than that of a full
agonist, even at maximal concentrations, is known as a:
A) Partial agonist
B) Inverse agonist
C) Competitive antagonist
,D) Non-competitive antagonist
Correct Answer: Partial agonist
Rationale: A partial agonist has lower efficacy than a full agonist and cannot produce
a maximal response even when all receptors are occupied. An inverse agonist reduces
baseline activity, while competitive and non-competitive antagonists block agonist
effects without producing a response.
3. Which pharmacokinetic parameter is defined as the proportion of an administered
drug that reaches systemic circulation in an unchanged form?
A) Bioavailability
B) Therapeutic index
C) Half-life
D) Clearance
Correct Answer: Bioavailability
Rationale: Bioavailability (F) measures the fraction of an administered dose that enters
systemic circulation unchanged. The therapeutic index is a safety ratio, half-life is the
time for drug concentration to decrease by 50%, and clearance is the volume of blood
cleared of drug per unit time.
4. A patient with cirrhosis is prescribed a medication that undergoes extensive first-pass
hepatic metabolism. The nurse practitioner anticipates which change in bioavailability?
, A) Decreased bioavailability due to impaired absorption
B) Increased bioavailability due to reduced first-pass metabolism
C) Unchanged bioavailability because first-pass metabolism occurs in the intestines
D) Variable bioavailability depending on renal function
Correct Answer: Increased bioavailability due to reduced first-pass metabolism
Rationale: Cirrhosis reduces hepatic function, decreasing first-pass metabolism and
increasing the fraction of drug reaching systemic circulation. This can lead to higher
drug levels and increased risk of toxicity, often requiring dose reduction.
5. A medication with a narrow therapeutic index requires which monitoring approach?
A) Less frequent monitoring due to a wide safety margin
B) Close monitoring of serum drug levels
C) No special precautions
D) Higher doses to ensure efficacy
Correct Answer: Close monitoring of serum drug levels
Rationale: Drugs with a narrow therapeutic index have a small margin between
therapeutic and toxic doses, making serum level monitoring essential. Examples include
digoxin, lithium, warfarin, and phenytoin. Monitoring ensures levels remain within the
therapeutic range.
